Don't forget to check out our new blog!! Read it here➡️ bit.ly/3OjDNPt

Titled: 'PRMT5: A New Epigenetic Target in the Battle Against Cardiac Fibrosis and Heart Failure'
_______
#Epigenetics #PRMT5 #ActiveMotif #Blog

This latest review examines the clinical relevance of #PRMT5 in various #Cancers, its role in #TumorImmunology, the trials involving PRMT5 #inhibitors, offering insights into future directions for PRMT5-targeted therapy. #medsky

#OpenAccess: www.sciencedirect.com/science/arti...

BeiGene's $150M Deal with CSPC Zhongqi: A Bold Move to Compete with Amgen in Cancer Drug Combinations BeiGene is making a significant move in the oncology space with a $150 million deal to license SYH2039, a promising MAT2A inhibitor from fellow Chinese company CSPC Zhongqi Pharmaceutical Technology. ...

www.linkedin.com/pulse/beigen...

BeiGene's $150M Deal with CSPC Zhongqi: A Bold Move to Compete with Amgen in Cancer Drug Combinations

kstrategyand.com/pharma-news

#BeiGene #CSPC #CancerResearch #Oncology #PRMT5 #DrugCombination #InnovationInHealthcare #Humanteconomy #Humantec #KStrategyand